Table 1.
Engraftment of EGFP+ cells in SCID-hu and RAG-hu Thy/Liv implants
| Cells | Time in coculture, days | % EGFP+ |
|||
|---|---|---|---|---|---|
| Week 3 | Week 4 | Week 5 | Week 6 | ||
| Experiment 1 | |||||
| CD133 | 10 | NT | 0.44 | NT | NT |
| CD133 | 10 | NT | 0.42 | NT | 5.6 |
| CD133 | 10 | 2.6 | NT | 0.16 | NT |
| CD34 | 10 | 2 | NT | 5.8 | NT |
| CD34 | 10 | 1 | NT | NT | NT |
| CD34 | 14 | 4 | NT | 0.6 | NT |
| Experiment 2 | |||||
| CD133 | 7 | 0.33 | NT | 6.2 | NT |
| CD133 | 11 | 0.1 | 1.8 | 2.89 | NT |
| CD133 | 11 | NT | 3.45 | NT | NT |
| CD34 | 7 | NT | 0.47 | NT | NT |
| CD34 | 11 | 0.14 | NT | 0.71 | NT |
| Experiment 3 | |||||
| CD133 | 10 | NT | 24.4 | NT | NT |
| CD133 | 10 | NT | NT | 23.1 | NT |
| CD133 | 10 | NT | NT | 18.6 | NT |
| CD34 | 10 | NT | 3.1 | NT | NT |
| CD34 | 10 | NT | NT | 15.6 | NT |
| CD34 | 10 | NT | NT | 8.7 | NT |
Thy/Liv implants in SCID-hu (experiments 1 and 2) and RAG-hu (experiment 3) mice received direct injections of progenitor cells derived from EGFP-labeled H1 cells cocultured on OP9 cells for various times. Progenitor cells were enriched for expression of CD34 or for CD133+/CD34− phenotype before injection as indicated. Implants were assessed for engraftment at the times indicated by flow cytometric analysis first by gating on human CD45 and subsequently by quantitating the percentage of CD45+/GFP+ cells. NT, not tested.